Oct 2026· JCO Oncology Practice· Vol 22, pp. 366-366· 0 citations
TL;DR
ICI-based therapy in GI malignancies is associated with clinically significant toxicity-related healthcare utilization, particularly with combination regimens, and combination regimens consistently demonstrated greater toxicity-related healthcare utilization than monotherapy approaches.
Abstract
366
Background:
Immune checkpoint inhibitors (ICIs) improve outcomes across gastrointestinal (GI) malignancies but may increase healthcare utilization through severe immune-related adverse events (irAEs), hospitalization, corticosteroid exposure, and treatment discontinuation. We evaluated the pooled burden of severe toxicity associated with ICIs in GI malignancies.
Methods:
PubMed, Embase, and Cochrane databases were systematically searched for randomized and observational studies evaluating ICIs in colorectal, gastric/gastroesophageal, esophageal, hepatobiliary, pancreatic, and anal cancers. Outcomes included grade ≥3 treatment-related adverse events (TRAEs), treatment discontinuation, hospitalization, corticosteroid use, and toxicity-related mortality. A random-effects pooled proportion meta-analysis was performed to estimate incidence rates with 95% confidence intervals (CIs). Heterogeneity was assessed using I² statistics. Subgroup analyses compared ICI monotherapy versus combination regimens.
Results:
Eighteen studies involving 9,842 patients met inclusion criteria. The pooled incidence of grade ≥3 TRAEs with ICI-based therapy was 38.7% (95% CI, 33.1–44.5; I²=71%). Combination ICI regimens demonstrated significantly higher pooled grade ≥3 toxicity compared with ICI monotherapy (52.4% vs 24.8%). Treatment discontinuation due to toxicity occurred in 11.6% (95% CI, 8.9–14.7), while toxicity-related mortality occurred in 1.8% (95% CI, 1.1–2.7). Severe irAEs including colitis, hepatitis, pneumonitis, and endocrinopathies were major contributors to corticosteroid utilization, hospitalization, and treatment interruption. Combination regimens consistently demonstrated greater toxicity-related healthcare utilization than monotherapy approaches.
Conclusions:
ICI-based therapy in GI malignancies is associated with clinically significant toxicity-related healthcare utilization, particularly with combination regimens. Standardized irAE management pathways and proactive supportive care strategies may reduce preventable utilization while preserving the therapeutic benefit of immunotherapy.
In patients with EC receiving ICIs, the occurrence of irAEs may be a prognostic marker of favorable outcomes, however, wide PIs for PFS and ORR indicate that these associations may vary across future studies and immortal time bias may overestimate survival associations.
Background
Immune checkpoint inhibitor (ICI)-based combination strategies are increasingly evaluated in metastatic prostate cancer (mPCa), but their comparative safety profiles remain uncertain. We conducted a systematic review and network meta-analysis (NMA) to compare adverse event (AE) profiles of ICI-based strategi...
Qing-Yuan Wang, Chuan-Hai Hao, Jun Chen et al.· Frontiers in Medicine· 0 citations
Immune checkpoint inhibitors (ICIs) are effective for several tumor entities but cause immune-related adverse events (irAEs). These side effects may affect any organ and often lead to ICI discontinuation, hospitalization, long-term complications, or sequelae. To assess the burden of irAEs, this longitudinal observation...
L. Heinzerling, I. Seemann, A. Ingram et al.· Journal of immunotherapy· 0 citations
Direct head-to-head evidence comparing different immune checkpoint inhibitor (ICI)-based regimens for advanced gastric or gastroesophageal junction adenocarcinoma remains limited. This study aimed to synthesize direct and indirect evidence to evaluate efficacy and safety of relevant immunotherapy regimens and to pr...
Fu-Jiao Duan, Yi-Lin Li, Hui-Juan Liu et al.· Frontiers in Immunology· 0 citations
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy and safety in patients with chronic kidney disease (CKD) remain uncertain, as this population is frequently excluded from pivotal trials. We aimed to evaluate clinical outcomes of ICI therapy in patients with cancer and CKD....
R. Pereira Silva, M. Lourenço Ferreira, Davi R. S. G. Amorim et al.· Journal of Onco-Nephrology· 0 citations
This systematic review and network meta-analysis aimed to evaluate the incidence and safety ranking of hematological toxicities associated with targeted therapies for malignant solid tumors in RCTs.
PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to June 2026 for RCTs in adu...
Bo-Qiao Wen, Xin-Pu Han, Tian-Xiang Li et al.· Clinical Medicine Insights:...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.